

**WPR PLUS- methyl salicylate, menthol
International Brand Management, LLC**

Disclaimer: Most OTC drugs are not reviewed and approved by FDA, however they may be marketed if they comply with applicable regulations and policies. FDA has not evaluated whether this product complies.

WPR Plus

INDICATIONS AND USAGE

LDO Plus™ is a medicated Hydrogel wound dressing in a Metered Dose (MDOSE™) bottle containing lidocaine 4%, an amide type local anesthetic, indicated for: Painful wounds such as post-surgical incisions, cuts and abrasions.

DOSAGE

Apply to the affected area as directed. Maximum 12 pumps per day.

DOSAGE FORMS AND STRENGTHS

LDO Plus is a topical medicated hydrogel wound dressing. Each gram of LDO Plus contains 4% Lidocaine HCl USP (40mg).

CONTRAINDICATIONS

Traumatized mucosa, secondary bacterial infection of the area of proposed application and known hypersensitivity to any of the components.

Lidocaine Hydrochloride USP is contraindicated in patients with a known history of hypersensitivity to local anesthetics of the amide type.

WARNINGS AND PRECAUTIONS

For External Use Only. Avoid Contact with Eyes. If irritation or sensitivity occurs or infection appears, discontinue use and institute appropriate therapy.

LDO Plus should be used with caution in ill, elderly, debilitated patients and children who may be more sensitive to the systemic effects of Lidocaine Hydrochloride USP.

ADVERSE REACTIONS

Most common adverse reactions are redness or swelling at the application site. Less common side effects, such as sluggishness, confusion, slow breathing, low blood pressure, or slow heartbeat, may occur. To report SUSPECTED ADVERSE REACTIONS, contact Gensco Pharma at 866-608-6284 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DRUG INTERACTIONS

Prilocaine, Bupivacaine, Amyl nitrates/sodium nitrate/sodium thiosulfate, Dofetilide, Lomitapide, Beta-blockers (e.g., atenolol), Cimetidine, or Class 1 antiarrhythmic drugs (ex. Mexiletine). This may not be a complete list of all interactions that may occur. Ask your health care provider if LDO Plus may interact with other medicines that you take.

USE IN SPECIFIC POPULATIONS

Use in Pregnancy: Teratogenic Effects - Pregnancy Category B.

Nursing Mothers: It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Lidocaine Hydrochloride USP is administered to a nursing woman.

Pediatric use: Dosage in children should be reduced, commensurate with age, body weight and physical condition.

Geriatric use: No overall clinical differences in safety or effectiveness have been observed between the healthy elderly and other adult patients.

FULL PRESCRIBING INFORMATION: CONTENTS*

WARNING | 1 INDICATIONS AND USAGE | 2 DOSAGE AND ADMINISTRATION 2.1 Dosage for children 2.2 Administration | 3 DOSAGE FORMS AND STRENGTHS | 4 CONTRAINDICATIONS | 5 WARNINGS AND PRECAUTIONS | 6 ADVERSE REACTIONS 6.1 Central nervous system 6.2 Cardiovascular system 6.3 Allergic | 7 DRUG INTERACTIONS 7.1 Serious interactions 7.2 General interactions | 8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy 8.2 Labor and Delivery 8.3 Nursing Mothers 8.4 Pediatric Use 8.5 Geriatric Use | 9 OVER DOSAGE 9.1 Management of local anesthetic emergencies | 10 DESCRIPTION 10.0 Active Ingredients 10.2 Inactive Ingredients | 11 CLINICAL PHARMACOLOGY 11.1 Mechanism of Action 11.2 Onset of Anesthesia 11.3 Hemodynamics 11.4 Pharmacokinetics and Metabolism | 12 NONCLINICAL TOXICOLOGY 12.1 Carcinogenesis, Mutagenesis, Impairment of Fertility | 13 HOW SUPPLIED / STORAGE AND HANDLING

* Sections or subsections omitted from the prescribing information are not listed.

Warning:

FOR EXTERNAL USE ONLY. NOT FOR OPHTHALMIC USE. EXCESSIVE DOSAGE, OR SHORT INTERVALS BETWEEN DOSES, CAN RESULT IN HIGH PLASMA LEVELS OF LIDOCAINE AND SERIOUS ADVERSE EFFECTS, PATIENTS SHOULD BE INSTRUCTED TO STRICTLY ADHERE TO THE RECOMMENDED DOSAGE AND ADMINISTRATION GUIDELINES AS SET FORTH IN THIS PACKAGE INSERT. THE MANAGEMENT OF SERIOUS ADVERSE REACTIONS MAY REQUIRE THE USE OF RESUSCITATIVE EQUIPMENT, OXYGEN, AND OTHER RESUSCITATIVE DRUGS.

1. Indications

Painful wounds such as post-surgical incisions, ulcers, cuts and abrasions.

2. Dosage and Administration:

Each pump of the LDO Plus MDOSE bottle (30mL Airless Metered Dose bottle) (NDC:35781-0500-3) will deliver 0.25 mL of LDO Plus (10 mg Lidocaine Hydrochloride USP), enough to cover a 2 inch by 2 inch area of skin. A single application should not exceed 4 pumps of the MDOSE bottle, equal to 1 gram of LDO Plus, (40 mg of Lidocaine Hydrochloride USP).

No more than 12 pumps of the MDOSE bottle, approximately 3 grams of LDO Plus (120 mg Lidocaine Hydrochloride USP,) should be administered in any one day.

Although the incidence of adverse effects with LDO Plus is quite low, caution should be exercised, particularly when employing large amounts, since the incidence of adverse effects is directly proportional to the total dose of local anesthetic agent administered.

2.1 Dosage for children:

The recommend dose of LDO Plus varies as a function of age and weight. For children less than ten years who have a normal lean body mass and a normal lean body development, the maximum dose may be determined by the application of one of the standard pediatric drug formulas (e.g., Clark's rule). For

example, a child of five years weighing 50 lbs., the dose of lidocaine should not exceed 75-100 mg (approximately 1.9 to 2.5 grams of LDO Plus) when calculated according to Clark's rule. In general, the maximum amount of lidocaine administered should not exceed 4.5 mg/kg (2.0 mg/lb) of body weight of the child. Do not use on children under 2 unless directed by a physician.

2.2 Administration:

Apply as directed. Do not exceed 12 pumps in a twenty-four-hour (24-hour) period. One pump covers an area of 2 x2 inches.

3. Dosage Form and Strength:

LDO Plus is a topical medicated hydrogel wound dressing. Each gram of LDO Plus contains 4% Lidocaine Hydrochloride USP (40mg).

4. Contraindications:

Lidocaine Hydrochloride USP is contraindicated in patients with a known history of hypersensitivity to local anesthetics of the amide type or to other components of LDO Plus.

Do not use LDO Plus on traumatized mucosa or in the presence of secondary bacterial infection of the area of proposed application.

5. Warnings and Precautions:

If irritation or sensitivity occurs or infection appears, discontinue use and institute appropriate therapy. LDO Plus should be used with caution in ill, elderly, debilitated patients and children who may be more sensitive to the systemic effects of Lidocaine Hydrochloride USP. In case of accidental ingestion get medical help or contact poison control center right away.

6. Adverse Reactions:

Adverse experiences following the administration of Lidocaine Hydrochloride USP are similar in nature to those observed with other amide local anesthetic agents. These adverse experiences are, in general, dose-related and may result from high plasma levels caused by excessive dosage or rapid absorption, or may result from a hypersensitivity, idiosyncrasy or diminished tolerance on the part of the patient. Serious adverse experiences are generally systemic in nature. The following types are those most commonly reported:

6.1 Central nervous system:

CNS manifestations of Lidocaine toxicity are excitatory and/or depressant and may be characterized by lightheadedness, nervousness, apprehension, euphoria, confusion, dizziness, drowsiness, tinnitus, blurred or double vision, vomiting, sensations of heat, cold or numbness, twitching, tremors, convulsions, unconsciousness, respiratory depression and arrest. The excitatory manifestations may be very brief or may not occur at all, in which case the first manifestation of toxicity may be drowsiness merging into unconsciousness and respiratory arrest. Drowsiness following the administration of Lidocaine Hydrochloride USP is usually an early sign of a high blood level of the drug and may occur as a consequence of rapid absorption.

6.2 Cardiovascular system:

Cardiovascular manifestations of Lidocaine toxicity are usually depressant and are characterized by bradycardia, hypotension, and cardiovascular collapse, which may lead to cardiac arrest.

6.3 Allergic:

Allergic reactions are characterized by cutaneous lesions, urticaria, edema or anaphylactoid reactions. Allergic reactions may occur as a result of sensitivity either to the local anesthetic agent or to other components in the formulation. Allergic reactions as a result of sensitivity to Lidocaine Hydrochloride USP are extremely rare and, if they occur, should be managed by conventional means. The detection of sensitivity by skin testing is of doubtful value.

7. Drug Interactions:

7.1 Serious interactions: Antiarrhythmic Drugs: LDO Plus should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Bupivacaine liposome: Lidocaine Hydrochloride USP increases toxicity of Bupivacaine by increasing the free (unencapsulated) bupivacaine. Dofetilide: Lidocaine Hydrochloride USP increases effects of dofetilide thru pharmacodynamic synergism. Lomitapide: Lidocaine Hydrochloride USP increases levels of lomitapide by affecting hepatic/intestinal enzymes CYP3A4 metabolism.

7.2 General interactions:

Drugs metabolized via CYP3A4 enzyme: (ex. Antipsychotics, SSRIs, TCAs, many chemotherapeutics, calcium channel blockers, benzodiazepines) Lidocaine Hydrochloride USP may increase serum levels of many drugs metabolized by hepatic / intestinal CYP3A4 enzymes. Drugs that affect hepatic CYP1A2 enzyme: (ex. Quinoline antibiotics, cimetidine, barbiturates, benzodiazepines, erythromycin) May increase serum Lidocaine Hydrochloride USP levels by decreasing Lidocaine Hydrochloride USP metabolism by CYP1A2 enzyme.

8. Use in Specific Populations:

8.1 Use in Pregnancy: Teratogenic Effects of Lidocaine Hydrochloride USP. Pregnancy Category B. Reproduction studies have been performed in rats at doses up to 6.6 times the human dose and have revealed no evidence of harm to the fetus caused by Lidocaine Hydrochloride USP. There are, however, no adequate and well-controlled studies in pregnant women. Animal reproduction studies are not always predictive of human response. General consideration should be given to this fact before administering Lidocaine Hydrochloride USP to women of childbearing potential, especially during early pregnancy when maximum organogenesis takes place.

8.2 Labor and Delivery:

Lidocaine Hydrochloride USP is not contraindicated in labor and delivery. Should LDO Plus be used concomitantly with other products containing Lidocaine Hydrochloride USP, the total dose contributed by all formulations must be kept in mind.

8.3 Nursing Mothers:

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Lidocaine Hydrochloride USP is administered to a nursing woman.

8.4 Pediatric use:

Dosage in children should be reduced, commensurate with age, body weight and physical condition. Caution must be taken to avoid over dosage when applying LDO Plus to large areas of injured or abraded skin, since the systemic absorption of Lidocaine Hydrochloride USP may be increased under such conditions. Do not use on children under 2 unless directed by a physician

8.5 Geriatric use:

No overall clinical differences in safety or effectiveness have been observed between the healthy elderly and other adult patients.

9. Over Dosage:

Acute emergencies from local anesthetics are generally related to high plasma levels encountered during therapeutic use of local anesthetics. (see ADVERSE REACTIONS, WARNINGS, and PRECAUTIONS).

9.1 Management of local anesthetic emergencies:

The first consideration is prevention, best accomplished by careful and constant monitoring of cardiovascular and respiratory vital signs and the patient's state of consciousness after each local anesthetic administration. At the first sign of change, oxygen should be administered. The first step in the management of convulsions consists of immediate attention to the maintenance of a patent airway and assisted or controlled ventilation with oxygen and a delivery system capable of permitting immediate positive airway pressure by mask.


Immediately after the institution of these ventilatory measures, the adequacy of the circulation should be evaluated, keeping in mind that drugs used to treat convulsions sometimes depress the circulation when administered intravenously. Should convulsions persist despite adequate respiratory support, and if the status of the circulation permits, small increments of an ultra-short acting barbiturate (such as thiopental or thiamylal) or a benzodiazepine (such as diazepam) may be administered intravenously. The clinician should be familiar, prior to use of local anesthetics, with these anticonvulsant drugs. Supportive treatment of circulatory depression may require administration of intravenous fluids and, when appropriate, a vasopressor as directed by the clinical situation (e.g., ephedrine).

If not treated immediately, both convulsions and cardiovascular depression can result in hypoxia, acidosis, bradycardia, arrhythmias and cardiac arrest. If cardiac arrest should occur, standard cardiopulmonary resuscitative measures should be instituted.

Dialysis is of negligible value in the treatment of acute over dosage with Lidocaine Hydrochloride USP. The oral LD50 of Lidocaine HCl USP in non-fasted female rats is 459 (346-773) mg/kg (as the salt) and 214 (159-324) mg/kg (as the salt) in fasted female rats.

10. Description:

10.1 Active Ingredients: Each gram of LDO Plus contains Lidocaine Hydrochloride USP 4% (40 mg). Lidocaine Hydrochloride USP is chemically designated as acetamide, 2- (diethylamino)-N-(2,6-dimethylphenyl), and has the following structure:



10.2 Inactive Ingredients:

Polyethylene Glycol(PEG) 400 & Polyethylene Glycol 3350 as base, Oak Extract, Meadowsweet Extract, Zinc Acetate, and Water.

11. Clinical Pharmacology:

11.1 Mechanism of action:LDO Plus is a hydrated polymer (Hydrogel) wound dressing containing 4% w/w Lidocaine HCl USP. By providing moisture to the wound, LDO Plus creates a moist healing environment, which promotes granulation, epithelialization, and autolytic debridement. The high water content of hydrogel dressings cools the wound, producing pain relief that can last up to 6 hours. Dressing-change discomfort is also reduced because LDO Plus doesn't adhere to the wound surface.

LDO Plus releases Lidocaine Hydrochloride USP from the Neutral (pH 7-7.2) hydrogel to stabilize the neuronal membrane by inhibiting the ionic fluxes required for initiation and conduction of impulses, thereby effecting local anesthetic action.

11.2 Onset of anesthesia:

LDO Plus effects local, topical anesthesia. The onset of action is 3-5 minutes.

11.3 Hemodynamics :

Excessive blood levels may cause changes in cardiac output, total peripheral resistance, and mean arterial pressure. These changes may be attributable to a direct depressant effect of the local anesthetic agent on various components of the cardiovascular system.

11.4 Pharmacokinetics and metabolism:

Lidocaine Hydrochloride USP may be absorbed following topical administration to mucous membranes or open wounds, its rate and extent of absorption depending upon the specific site of application, duration of exposure, concentration, and total dosage. In general, the rate of absorption of local anesthetic agents following topical application occurs most rapidly after intratracheal administration. Lidocaine Hydrochloride USP is also well-absorbed from the gastrointestinal tract, but little intact drug appears in the circulation because of biotransformation in the liver. Lidocaine Hydrochloride USP is metabolized rapidly by the liver, and metabolites and unchanged drug are excreted by the kidneys. Biotransformation includes oxidative N-dealkylation, ring hydroxylation, cleavage of the amide linkage, and conjugation. N-dealkylation, a major pathway of biotransformation, yields the metabolites monoethylglycinexylidide and glycinexylidide. The pharmacological/toxicological actions of these metabolites are similar to, but less potent than, those of Lidocaine Hydrochloride USP. Approximately 90% of Lidocaine Hydrochloride USP administered is excreted in the form of various metabolites, and less than 10% is excreted unchanged. The primary metabolite in urine is a conjugate of 4-hydroxy-2,6-dimethylaniline. The plasma binding of Lidocaine Hydrochloride USP is dependent on drug concentration, and the fraction bound decreases with increasing concentration. At concentrations of 1 to 4 µg of free base per mL, 60 to 80 percent of Lidocaine Hydrochloride USP is protein bound. Binding is also dependent on the plasma concentration of the alpha-1-acid glycoprotein. Lidocaine Hydrochloride USP crosses the blood-brain and placental barriers, presumably by passive diffusion. Studies of Lidocaine Hydrochloride USP metabolism following intravenous bolus injections have shown that the elimination half-life of this agent is typically 1.5 to 2.0 hours. Because of the rapid rate at which Lidocaine Hydrochloride USP is metabolized, any condition that affects liver function may alter Lidocaine Hydrochloride USP kinetics. The half-life may be prolonged two-fold or more in patients with liver dysfunction. Renal dysfunction does not affect Lidocaine Hydrochloride USP kinetics but may increase the accumulation of metabolites.

12. Non-Clinical Toxicity:

Studies of Lidocaine Hydrochloride USP in animals to evaluate the carcinogenic and mutagenic potential or the effect on fertility have not been conducted.

13. How Supplied / Storage and Handling:

HOW SUPPLIED:LDO Plus (Medicated Hydrogel containing Lidocaine HCl USP 4%)
1.0 oz (28.5g) 30mL Airless Pump - NDC 35781-0500-3

STORE AND DISPOSE OF THIS AND ALL MEDICATIONS OUT OF REACH OF CHILDREN AND PETS. All prescriptions using this product shall be pursuant to state statutes as applicable. This product may be administered only under a physician's supervision. There are no implied or explicit claims on the therapeutic equivalence. Store at 25°C (77°F); excursions permitted to 15°-30°C (59°-86° F). See USP Controlled Room Temperature. Protect from freezing.

Manufactured for: Gensco Laboratories, 8550 NW 33rd Street, Suite 200, Doral, FL 33122
MDOSE™ is a registered trademark of Gensco Laboratories, LLC.

Active Ingredients :

Methyl Salicylate....30.00%
Menthol.....10.00%

Purpose

Topical Analgesic

Uses:

temporarily relieves the minor aches and pains of muscles and joints associated with:
-simple backache -arthritis -sprains -bruises -sprains

Warnings:

For external use only

Do not use:

- on wounds or damaged skin -with a heating pad
- on a child under 12 years of age with arthritis-like conditions

Ask a doctor before use

if you have redness over the affected area

When using this product:

- avoid contact with eyes or mucous membranes
- do not bandage tightly

Stop use and ask a doctor if:

- condition worsens or symptoms persist for more than 7 days
- symptoms clear up and occur again within a few days
- excessive skin irritation occurs

Keep out of reach of children

to avoid accidental ingestion. If swallowed, get medical help or contact a Poison Control Center immediately

Directions:

- use only as directed
- adults and children 12 years of age and older:
apply to affected area not more than 3 to 4 times daily
- children under 12 years of age: ask a doctor

Inactive Ingredients:

Aloe Barbadensis Leaf (Aloe Vera Gel) Juice, Aqua (Deionized Water), Arnica Montana Flower Extract, Boswellia Serrata Extract, Calendula Officinalis Extract, Cannabis Sativa (Hemp) Seed Oil,

Cetearyl Olivat, Cetyl Alcohol, Chondrotin Sulfate, Gluconolactone, Glucosamine Sulfate, Glycerin, Glyceryl Stearate, Helianthus Annuus (Sunflower) Oil, Magnesium Sulfate, Methylsulfonylmethane (MSM), Sodium Benzoate, Sodium Laurylglucosides Hydroxypropylsulfonate, SorbitanOlivat, Tapioca Starch, Xanthan Gum, Zemea (Corn) Propanediol.

WPR Plus Kit (69837-300-03)

WPR Plus: Lidocaine HCl USP 4% 30ml/Amplify Relief MM 118g

Drug Place Glasgow, KY 42141

69837-300-03

[LDO Plus logo]

HYDROGEL + TOPICAL ANESTHETIC (LIDOCAINE HCl 4%)

1.0 fl oz (30ml Bottle) NDC 35781-0500-3

READ THIS INFORMATION BEFORE PRESCRIBING THIS PRODUCT

INDICATIONS AND USAGE

LDO Plus™ is a medicated Hydrogel wound dressing in a Metered Dose (MDOSE™) bottle containing Lidocaine 4%, an amide type local anesthetic, indicated for: Painful wounds such as post-surgical incisions, cuts and abrasions.

DOSAGE

Apply to the affected area as directed. Maximum 12 pumps per day.

DOSAGE FORMS AND STRENGTHS

LDO Plus is a topical medicated hydrogel wound dressing. Each gram of LDO Plus contains 4% Lidocaine HCl USP (40mg).

CONTRAINDICATIONS

Traumatized mucosa, secondary bacterial infection of the area of proposed application and known hypersensitivity to any of the components.

Lidocaine Hydrochloride USP is contraindicated in patients with a known history of hypersensitivity to local anesthetics of the amide type.

WARNINGS AND PRECAUTIONS

For External Use Only. Avoid Contact with Eyes. If irritation or sensitivity occurs or infection appears, discontinue use and institute appropriate therapy.

LDO Plus should be used with caution in ill, elderly, debilitated patients and children who may be more sensitive to the systemic effects of Lidocaine Hydrochloride USP.

ADVERSE REACTIONS

Most common adverse reactions are redness or swelling at the application site. Less common side effects, such as sluggishness, confusion, slow breathing, low blood pressure, or slow heartbeat, may occur. To report SUSPECTED ADVERSE REACTIONS, contact Genesco Pharma at 866-608-6284 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DRUG INTERACTIONS

Prilocaine, Bupivacaine, Amyl nitrate/sodium nitrate/sodium thiosulfate, Dofetilide, Lomitapide, Beta-blockers (e.g., atenolol), Cimetidine, or Class 1 antiarrhythmic drugs (ex. Mexiletine). *This may not be a complete list of all interactions that may occur. Ask your health care provider if LDO Plus may interact with other medicines that you take.*

USE IN SPECIFIC POPULATIONS

Use in Pregnancy: Teratogenic Effects - Pregnancy Category B.

Nursing Mothers: It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Lidocaine Hydrochloride USP is administered to a nursing woman.

Pediatric use: Dosage in children should be reduced, commensurate with age, body weight and physical condition.

Geriatric use: No overall clinical differences in safety or effectiveness have been observed between the healthy elderly and other adult patients.

FULL PRESCRIBING INFORMATION: CONTENTS*

WARNING | 1 INDICATIONS AND USAGE | 2 DOSAGE AND ADMINISTRATION 2.1 Dosage for children 2.2 Administration | 3 DOSAGE FORMS AND STRENGTHS | 4 CONTRAINDICATIONS | 5 WARNINGS AND PRECAUTIONS | 6 ADVERSE REACTIONS 6.1 Central nervous system 6.2 Cardiovascular system 6.3 Allergic | 7 DRUG INTERACTIONS 7.1 Serious interactions 7.2 General interactions | 8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy 8.2 Labor and Delivery 8.3 Nursing Mothers 8.4 Pediatric Use 8.5 Geriatric Use | 9 OVER DOSAGE 9.1 Management of local anesthetic emergencies | 10 DESCRIPTION 10.0 Active Ingredients 10.2 Inactive Ingredients | 11 CLINICAL PHARMACOLOGY 11.1 Mechanism of Action 11.2 Onset of Anesthesia 11.3 Hemodynamics 11.4 Pharmacokinetics and Metabolism | 12 NONCLINICAL TOXICOLOGY 12.1 Carcinogenesis, Mutagenesis, Impairment of Fertility | 13 HOW SUPPLIED / STORAGE AND HANDLING

* Sections or subsections omitted from the prescribing information are not listed.

Warning: FOR EXTERNAL USE ONLY. NOT FOR OPHTHALMIC USE. EXCESSIVE DOSAGE, OR SHORT INTERVALS BETWEEN DOSES, CAN RESULT IN HIGH PLASMA LEVELS OF LIDOCAINE AND SERIOUS ADVERSE EFFECTS. PATIENTS SHOULD BE INSTRUCTED TO STRICTLY ADHERE TO THE RECOMMENDED DOSAGE AND ADMINISTRATION GUIDELINES AS SET FORTH IN THIS PACKAGE INSERT. THE MANAGEMENT OF SERIOUS ADVERSE REACTIONS MAY REQUIRE THE USE OF RESUSCITATIVE EQUIPMENT, OXYGEN, AND OTHER RESUSCITATIVE DRUGS.

1. Indications: Painful wounds such as post-surgical incisions, ulcers, cuts and abrasions.

2. Dosage and Administration: Each pump of the LDO Plus MDOSE bottle (30mL Airless Metered Dose bottle) (NDC:35781-0500-3) will deliver 0.25 mL of LDO Plus (10 mg Lidocaine Hydrochloride USP), enough to cover a 2 inch by 2 inch area of skin. A single application should not exceed 4 pumps of the MDOSE bottle, equal to 1 gram of LDO Plus, (40 mg of Lidocaine Hydrochloride USP).

No more than 12 pumps of the MDOSE bottle, approximately 3 grams of LDO Plus (120 mg Lidocaine Hydrochloride USP,) should be administered in any one day.

Although the incidence of adverse effects with LDO Plus is quite low, caution should be exercised, particularly when employing large amounts, since the incidence of adverse effects is directly proportional to the total dose of local anesthetic agent administered.

2.1 Dosage for children: The recommend dose of LDO Plus varies as a function of age and weight. For children less than ten years who have a normal lean body mass and a normal lean body development, the maximum dose may be determined by the application of one of the standard pediatric drug formulas (e.g., Clark's rule). For example, a child of five years weighing 50 lbs., the dose of lidocaine should not exceed 75-100 mg (approximately 1.9 to 2.5 grams of LDO Plus) when calculated according to Clark's rule. In general, the maximum amount of lidocaine administered should not exceed 4.5 mg/kg (2.0 mg/lb) of body weight of the child. Do not use on children under 2 unless directed by a physician.

2.2 Administration: Apply as directed. Do not exceed 12 pumps in a twenty-four-hour (24-hour) period. One pump covers an area of 2x2 inches.

3. Dosage Form and Strength: LDO Plus is a topical medicated hydrogel wound dressing. Each gram of LDO Plus contains 4% Lidocaine Hydrochloride USP (40mg).

4. Contraindications: Lidocaine Hydrochloride USP is contraindicated in patients with a known history of hypersensitivity to local anesthetics of the amide type or to other components of LDO Plus.

Do not use LDO Plus on traumatized mucosa or in the presence of secondary bacterial infection of the area of proposed application.

5. Warnings and Precautions: If irritation or sensitivity occurs or infection appears, discontinue use and institute appropriate therapy. LDO Plus should be used with caution in ill, elderly, debilitated patients and children who may be more sensitive to the systemic effects of Lidocaine Hydrochloride USP. In case of accidental ingestion get medical help or contact poison control center right away.

6. Adverse Reactions: Adverse experiences following the administration of Lidocaine Hydrochloride USP are similar in nature to those observed with other amide local anesthetic agents. These adverse experiences are, in general, dose-related and may result from high plasma levels caused by excessive dosage or rapid absorption, or may result from a hypersensitivity, idiosyncrasy or diminished tolerance on the part of the patient. Serious adverse experiences are generally systemic in nature. The following types are those most commonly reported:

6.1 Central nervous system: CNS manifestations of Lidocaine toxicity are excitatory and/or depressant and may be characterized by lightheadedness, nervousness, apprehension, euphoria, confusion, dizziness, drowsiness, tinnitus, blurred or double vision, vomiting, sensations of heat, cold or numbness, twitching, tremors, convulsions, unconsciousness, respiratory depression and arrest. The excitatory manifestations may be very brief or may not occur at all, in which case the first manifestation of toxicity may be drowsiness merging into unconsciousness and respiratory arrest. Drowsiness following the administration of Lidocaine Hydrochloride USP is usually an early sign of a high blood level of the drug and may occur as a consequence of rapid absorption.

6.2 Cardiovascular system: Cardiovascular manifestations of Lidocaine toxicity are usually depressant and are characterized by bradycardia, hypotension, and cardiovascular collapse, which may lead to cardiac arrest.

6.3 Allergic: Allergic reactions are characterized by cutaneous lesions, urticaria, edema or anaphylactoid reactions. Allergic reactions may occur as a result of sensitivity either to the local anesthetic agent or to other components in the formulation. Allergic reactions as a result of sensitivity to Lidocaine Hydrochloride USP are extremely rare and, if they occur, should be managed by conventional means. The detection of sensitivity by skin testing is of doubtful value.

7. Drug Interactions:

7.1 Serious interactions: Antiarrhythmic Drugs: LDO Plus should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. Bupivacaine liposome: Lidocaine Hydrochloride USP increases toxicity of Bupivacaine by increasing the free (unencapsulated) bupivacaine. Dofetilide: Lidocaine Hydrochloride USP increases effects of dofetilide thru pharmacodynamic synergism. Lomitapide: Lidocaine Hydrochloride USP increases levels of lomitapide by affecting hepatic/intestinal enzymes CYP3A4 metabolism.

7.2 General interactions: Drugs metabolized via CYP3A4 enzyme: (ex. Antipsychotics, SSRIs, TCAs, many chemotherapeutics, calcium channel blockers, benzodiazepines) Lidocaine Hydrochloride USP may increase serum levels of many drugs metabolized by hepatic / intestinal CYP3A4 enzymes. Drugs that affect hepatic CYP1A2 enzyme: (ex. Quinolone antibiotics, cimetidine, barbiturates, benzodiazepines, erythromycin) May increase serum Lidocaine Hydrochloride USP levels by decreasing Lidocaine Hydrochloride USP metabolism by CYP1A2 enzyme.

8. Use in Specific Populations:

8.1 Use in Pregnancy: Teratogenic Effects of Lidocaine Hydrochloride USP. Pregnancy Category B. Reproduction studies have been performed in rats at doses up to 6.6 times the human dose and have revealed no evidence of harm to the fetus caused by Lidocaine Hydrochloride USP. There are, however, no adequate and well-controlled studies in pregnant women. Animal reproduction studies are not always predictive of human response. General consideration should be given to this fact before administering Lidocaine Hydrochloride USP to women of childbearing potential, especially during early pregnancy when maximum organogenesis takes place.

8.2 Labor and Delivery: Lidocaine Hydrochloride USP is not contraindicated in labor and delivery. Should LDO Plus be used concomitantly with other products containing Lidocaine Hydrochloride USP, the total dose contributed by all formulations must be kept in mind.

8.3 Nursing Mothers: It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Lidocaine Hydrochloride USP is administered to a nursing woman.

8.4 Pediatric use: Dosage in children should be reduced, commensurate with age, body weight and physical condition. Caution must be taken to avoid over dosage when applying LDO Plus to large areas of injured or abraded skin, since the systemic absorption of Lidocaine Hydrochloride USP may be increased under such conditions. Do not use on children under 2 unless directed by a physician.

8.5 Geriatric use: No overall clinical differences in safety or effectiveness have been observed between the healthy elderly and other adult patients.

9. Over Dosage: Acute emergencies from local anesthetics are generally related to high plasma levels encountered during therapeutic use of local anesthetics. (see ADVERSE REACTIONS, WARNINGS, and PRECAUTIONS).—

9.1 Management of local anesthetic emergencies: The first consideration is prevention, best accomplished by careful and constant monitoring of cardiovascular and respiratory vital signs and the patient's state of consciousness after each local anesthetic administration. At the first sign of change, oxygen should be administered. The first step in the management of convulsions consists of immediate attention to the maintenance of a patent airway and assisted or controlled ventilation with oxygen and a delivery system capable of permitting immediate positive airway pressure by mask.

Immediately after the institution of these ventilatory measures, the adequacy of the circulation should be evaluated, keeping in mind that drugs used to treat convulsions sometimes depress the circulation when administered intravenously. Should convulsions persist despite adequate respiratory support, and if the status of the circulation permits, small increments of an ultra-short acting barbiturate (such as thiopental or thiamylal) or a benzodiazepine (such as diazepam) may be administered intravenously. The clinician should be familiar, prior to use of local anesthetics, with these anticonvulsant drugs. Supportive treatment of circulatory depression may require administration of intravenous fluids and, when appropriate, a vasopressor as directed by the clinical situation (e.g., ephedrine).

If not treated immediately, both convulsions and cardiovascular depression can result in hypoxia, acidosis, bradycardia, arrhythmias and cardiac arrest. If cardiac arrest should occur, standard cardiopulmonary resuscitative measures should be instituted.

Dialysis is of negligible value in the treatment of acute over dosage with Lidocaine Hydrochloride USP. The oral LD50 of Lidocaine HCl USP in non-fasted female rats is 459 (346-773) mg/kg (as the salt) and 214 (159-324) mg/kg (as the salt) in fasted female rats.

10. Description:

10.1 Active Ingredients: Each gram of LDO Plus contains Lidocaine Hydrochloride USP 4% (40 mg). Lidocaine Hydrochloride USP is chemically designated as acetamide, 2- (diethylamino)-N-(2,6-dimethylphenyl), and has the following structure:

10.2 Inactive Ingredients: Polyethylene Glycol(PEG) 400 & Polyethylene Glycol 3350 as base, Oak Extract, Meadowsweet Extract, Zinc Acetate, and Water.

11. Clinical Pharmacology:

11.1 Mechanism of action:LDO Plus is a hydrated polymer (Hydrogel) wound dressing containing 4% w/w Lidocaine HCl USP. By providing moisture to the wound, LDO Plus creates a moist healing environment, which promotes granulation, epithelialization, and autolytic debridement. The high water content of hydrogel dressings cools the wound, producing pain relief that can last up to 6 hours. Dressing-change discomfort is also reduced because LDO Plus doesn't adhere to the wound surface.

LDO Plus releases Lidocaine Hydrochloride USP from the Neutral (pH 7-7.2) hydrogel to stabilize the neuronal membrane by inhibiting the ionic fluxes required for initiation and conduction of impulses, thereby effecting local anesthetic action.

11.2 Onset of anesthesia:LDO Plus effects local, topical anesthesia. The onset of action is 3-5 minutes.

11.3 Hemodynamics: Excessive blood levels may cause changes in cardiac output, total peripheral resistance, and mean arterial pressure. These changes may be attributable to a direct depressant effect of the local anesthetic agent on various components of the cardiovascular system.

11.4 Pharmacokinetics and metabolism: Lidocaine Hydrochloride USP may be absorbed following topical administration to mucous membranes or open wounds, its rate and extent of absorption depending upon the specific site of application, duration of exposure, concentration, and total dosage. In general, the rate of absorption of local anesthetic agents following topical application occurs most rapidly after intratracheal administration. Lidocaine Hydrochloride USP is also well-absorbed from the gastrointestinal tract, but little intact drug appears in the circulation because of biotransformation in the liver. Lidocaine Hydrochloride USP is metabolized rapidly by the liver, and metabolites and unchanged drug are excreted by the kidneys. Biotransformation includes oxidative N-dealkylation, ring hydroxylation, cleavage of the amide linkage, and conjugation. N-dealkylation, a major pathway of biotransformation, yields the metabolites monoethylglycinexylidide and glycinexylidide. The pharmacological/toxicological actions of these metabolites are similar to, but less potent than, those of Lidocaine Hydrochloride USP. Approximately 90% of Lidocaine Hydrochloride USP administered is excreted in the form of various metabolites, and less than 10% is excreted unchanged. The primary metabolite in urine is a conjugate of 4-hydroxy-2,6-dimethylaniline. The plasma binding of Lidocaine Hydrochloride USP is dependent on drug concentration, and the fraction bound decreases with increasing concentration. At concentrations of 1 to 4 µg of free base per mL, 60 to 80 percent of Lidocaine Hydrochloride USP is protein bound. Binding is also dependent on the plasma concentration of the alpha-1-acid glycoprotein. Lidocaine Hydrochloride USP crosses the blood-brain and placental barriers, presumably by passive diffusion. Studies of Lidocaine Hydrochloride USP metabolism following intravenous bolus injections have shown that the elimination half-life of this agent is typically 1.5 to 2.0 hours. Because of the rapid rate at which Lidocaine Hydrochloride USP is metabolized, any condition that affects liver function may alter Lidocaine Hydrochloride USP kinetics. The half-life may be prolonged two-fold or more in patients with liver dysfunction. Renal dysfunction does not affect Lidocaine Hydrochloride USP kinetics but may increase the accumulation of metabolites.

Factors such as acidosis and the use of CNS stimulants and depressants affect the CNS levels of Lidocaine Hydrochloride USP required to produce overt systemic effects. Objective adverse manifestations become increasingly apparent with increasing venous plasma levels above 6.0 µg free base per mL. In the rhesus monkey arterial blood levels of 18-21 µg/mL have been shown to be threshold for convulsive activity

12. Non-Clinical Toxicity: Studies of Lidocaine Hydrochloride USP in animals to evaluate the carcinogenic and mutagenic potential or the effect on fertility have not been conducted.

13. How Supplied / Storage and Handling:

HOW SUPPLIED:LDO Plus (Medicated Hydrogel containing Lidocaine HCl USP 4%)

1.0 oz (28.5g) 30mL Airless Pump - NDC 35781-0500-3

STORE AND DISPOSE OF THIS AND ALL MEDICATIONS OUT OF REACH OF CHILDREN AND PETS. All prescriptions using this product shall be pursuant to state statutes as applicable. This product may be administered only under a physician's supervision. There are no implied or explicit claims on the therapeutic equivalence. Store at 25°C (77°F); excursions permitted to 15°-30°C (59°-86° F). See USP Controlled Room Temperature. Protect from freezing.

Manufactured for: Gensco Laboratories, 8550 NW 33rd Street, Suite 200, Doral, FL 33122

MDOSE™ is registered trademark of Gensco Laboratories, LLC.

AMPLify Relief MM, 118mL (69837-019-01)

AMPLIFY RELIEF MM- methyl salicylate, menthol cream
International Brand Management, LLC

Disclaimer: Most OTC drugs are not reviewed and approved by FDA, however they may be marketed if they comply with applicable regulations and policies. FDA has not evaluated whether this product complies.

Active Ingredients :

Methyl Salicylate....30.00%

Menthol.....10.00%

Purpose

Topical Analgesic

Topical Analgesic

Uses : temporarily relieves the minor aches and pains of muscles and joints associated with:

-simple backache -arthritis -sprains -bruises -sprains

Warnings :

For external use only

Do not use:

-on wounds or damaged skin -with a heating pad

-on a child under 12 years of age with arthritis-like conditions

Ask a doctor before use if you have redness over the affected area

When using this product:

-avoid contact with eyes or mucous membranes

-do not bandage tightly

Stop use and ask a doctor if:

-condition worsens or symptoms persist for more than 7 days

-symptoms clear up and occur again within a few days

-excessive skin irritation occurs

Keep out of reach of children to avoid accidental ingestion. If swallowed, get medical help or contact a Poison Control Center immediately

Directions :

-use only as directed

-adults and children 12 years of age and older:

apply to affected area not more than 3 to 4 times daily

-children under 12 years of age: ask a doctor

Inactive Ingredients : Aloe Barbadensis Leaf (Aloe Vera Gel) Juice, Aqua (Deionized Water), Arnica Montana Flower Extract, Boswellia Serrata Extract, Calendula Officinalis Extract, Cannabis Sativa (Hemp) Seed Oil, Cetearyl Oliviate, Cetyl Alcohol, Chondroitin Sulfate, Gluconolactone, Glucosamine Sulfate, Glycerin, Glyceryl Stearate, Helianthus Annuus (Sunflower) Oil, Magnesium Sulfate, Methylsulfonylmethane (MSM), Sodium Benzoate, Sodium Laurylglucosides Hydroxypropylsulfonate, Sorbitan Oliviate, Tapioca Starch, Xanthan Gum, Zemea (Corn) Propanediol.

Distributed BY:

Drug Place Inc.

Glasgow, KY 42141

800-992-1190

NDC 69837-300-03

Rx Only

WPR Plus

Wound Healing System

Lidocaine HCl USP 4%
(4%-2x30ml)

AMPLify Relief MM
(Menthol 10.00% / Methyl Salicylate 30.00%)
1x118g

See enclosed Insert for full prescribing information.

A soothing hydrogel wound dressing that promotes a moist wound environment that is ideal for the healing process.

DIRECTIONS

Cleanse the wound and blow it dry. Apply a thin layer of LDO Plus to the wound surface and the skin immediately surrounding the wound 3-4 times daily.

INDICATIONS

- Stage I - IV pressure ulcers
- Venous stasis ulcers
- Ulcerations caused by mixed vascular etiologies
- Diabetic skin ulcers
- First and second degree burns
- Post-surgical incisions, cuts and abrasions.

WARNINGS

Do not use this product if you are allergic to any ingredients. If conditions worsen or does not improve within 7 days, consult a physician. Do not use on children under 2 years of age without consulting a physician. Avoid contact with eyes. Do not use in large quantities.

Keep this and all medication out of reach of children.

STORAGE

Store at 25°C (77°F); excursions permitted to 15°-30°C (59°-86°F).
Protect from freezing [See USP Controlled Room Temperature].

Distributed by:
Drug Place Inc.
321 Matthews Mill Rd.
Glasgow, KY 42141

FOR QUESTIONS OR
COMMENTS:
800-992-1190

Lot:

EXP:



NDC 69837-019-01

AMPLify Relief MM

Topical Pain Relief Cream (Menthol 10% / Methyl Salicylate 30%)

4 fl oz / 118 mL

Drug Facts

Active Ingredients:	Purpose
Methyl Salicylate.....30.00%	Topical Analgesic
Menthol.....10.00%	Topical Analgesic

Inactive Ingredients: Aloe Barbadosis Leaf (Aloe Vera Gel) Juice, Aqua (Deionized Water), Arnica Montana Flower Extract, Boswellia Serrata Extract, Calendula Officinalis Extract, Cannabis Sativa (Hemp) Seed Oil, Cetearyl Oliviate, Cetyl Alcohol, Chondroitin Sulfate, Gluconolactone, Glucosamine Sulfate, Glycerin, Glyceryl Stearate, Helianthus Annuus (Sunflower) Oil, Magnesium Sulfate, Methylsulfonylmethane (MSM), Sodium Benzoate, Sodium Laurylglucosides Hydroxypropylsulfonate, Sorbitan Oliviate, Tapioca Starch, Xanthan Gum, Zemea (Corn) Propanediol.

Uses: temporarily relieves the minor aches and pains of muscles and joints associated with:
 • simple backache • arthritis • strains • bruises • sprains

Warnings:
 For external use only.
 Do not use:
 • on wounds or damaged skin • with a heating pad
 • on a child under 12 years of age with arthritis-like conditions
 Ask a doctor before use if you have redness over the affected area.

When using this product:
 • avoid contact with eyes or mucous membranes
 • do not bandage tightly

Stop use and ask a doctor if:
 • condition worsens or symptoms persist for more than 7 days
 • symptoms clear up and occur again within a few days
 • excessive skin irritation occurs
 Keep out of reach of children to avoid accidental ingestion. If swallowed, get medical help or contact a Poison Control Center immediately.

Directions:
 • use only as directed
 • adults and children 12 years of age and older:
 apply to affected area not more than 3 to 4 times daily
 • children under 12 years of age: ask a doctor

Manufactured For:
19 & Pacific
 160 Greentree Drive, Suite 101
 Dover, Delaware 19904

**FOR QUESTIONS OR
 COMMENTS:
 800-992-1190**

WPR PLUS

methyl salicylate, menthol kit

Product Information

Product Type	HUMAN OTC DRUG	Item Code (Source)	NDC:69837-300
---------------------	----------------	---------------------------	---------------

Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:69837-300-03	1 in 1 KIT	06/01/2018	

Quantity of Parts

Part #	Package Quantity	Total Product Quantity
Part 1	1 TUBE	118 g

Part 1 of 1

AMPLIFY RELIEF MM

methyl salicylate, menthol cream

Product Information

Item Code (Source)	NDC:69837-019
Route of Administration	TOPICAL

Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
METHYL SALICYLATE (UNII: LAV5U5022Y) (SALICYLIC ACID - UNII:O414PZ4LPZ)	METHYL SALICYLATE	3 g in 10 g
MENTHOL (UNII: L7T10EIP3A) (MENTHOL - UNII:L7T10EIP3A)	MENTHOL	1 g in 10 g

Inactive Ingredients

Ingredient Name	Strength
ALOE VERA LEAF (UNII: ZY81Z83H0X)	
WATER (UNII: 059QF0KO0R)	
ARNICA MONTANA FLOWER (UNII: OZ0E5Y15PZ)	
INDIAN FRANKINCENSE (UNII: 4PW41QCO2M)	
HEMP (UNII: TD1MUT01Q7)	
CETEARYL OLIVATE (UNII: 58B69Q84JO)	
CETYL ALCOHOL (UNII: 936JST6JCN)	
GLUCONOLACTONE (UNII: WQ29KQ9POT)	
GLUCOSAMINE SULFATE (UNII: 1FW7WLR731)	
GLYCERIN (UNII: PDC6A3C0OX)	
GLYCERYL MONOSTEARATE (UNII: 230OU9XXE4)	
HELIANTHUS ANNUUS FLOWERING TOP (UNII: BKJ0J3D1BP)	
MAGNESIUM SULFATE, UNSPECIFIED FORM (UNII: DE08037SAB)	
DIMETHYL SULFONE (UNII: 9H4PO4Z4FT)	
SODIUM BENZOATE (UNII: OJ245FE5EU)	
SORBITAN OLIVATE (UNII: MDL271E3GR)	
STARCH, TAPIOCA (UNII: 24SC3U704I)	
XANTHAN GUM (UNII: TTV12P4NEE)	
CORN (UNII: 0N8672707O)	

Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:69837-019-01	1 in 1 CARTON		
1	NDC:69837-019-02	118 g in 1 TUBE; Type 0: Not a Combination Product		

Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
OTC monograph not final	part348	06/01/2018	

Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
OTC monograph not final	part348	06/01/2018	

Labeler - International Brand Management, LLC (079794940)

Revised: 7/2018

International Brand Management, LLC